Establishment Labs Third Quarter 2026 Financial Results - ESTABLISHMENT LABS HOLDINGS INC

Explicit Guidance:

• Full-Year 2026 Revenue: Raised to >$274 million (previously $269M–$271M).
• Full-Year 2026 Adjusted Gross Margin: Expected to be ~70.7%, aligned with year-to-date performance (down from prior guidance of 71.2%–72.2%).
• Full-Year 2026 Adjusted Operating Expenses: Unchanged at $195 million–$200 million.
• Full-Year 2026 Adjusted EBITDA: Guidance supports positive adjusted EBITDA for the full year.
• Full-Year 2026 Minimally Invasive Revenue: Updated expectation of >$40 million (previously >$35 million).
• Fiscal 2027 Revenue Growth: Forecast 25% year-over-year growth, driven by U.S. utilization, minimally invasive platform adoption, and OUS opportunities.
• Fiscal 2027 Adjusted Gross Margin: Anticipated improvement of 50–100 basis points over 2026 levels, dependent on geographic and channel mix.
• Fiscal 2027 Free Cash Flow: Target to sustain positive free cash flow after first quarter achieved in Q3 2026.
• FY2027 Cash Flow Context: 2025/2026 debt refinancing provides >$5 million quarterly cash interest savings during the initial pick period, enhancing flexibility for U.S. expansion and R&D.

Business-Segment Outlook:

• U.S. Business: Focus shifting from account acquisition to utilization within existing 2,100+ accounts; current Motiva utilization at 43% among users with room to grow; U.S. revenue share expected to exceed 35% of total revenue in 2027.
• Minimally Invasive Platform: U.S. segment expected to exceed 15% of total revenue in 2027; OUS minimally invasive revenue grew 16% YoY; strategy to capture new surgeons and expand existing accounts via MIA and Preserve.
• Preserve Product: Aiming to train 500 surgeons by end of 2026 (current: 400+); shifting focus to increasing utilization among trained surgeons (22% of augmentation procedures for surveyed surgeons); 88% of surveyed surgeons report attracting new patients.
• Motiva Implants: October FDA approval for additional sizes (including 105 cc) expected commercial availability before year-end; projected to address 10% of the U.S. market previously unaddressed due to size constraints; global size expansions planned for MIA (up to 300 cc) and Preserve (up to 380 cc).
• Reconstruction: Building commercial infrastructure and hospital relationships via Motiva Flora Tissue Expander (available in 350+ facilities); reconstruction submission progressing with BMO inspections complete; expecting approval either end of 2026 or Q1 2027; revenue impact expected to materialize in the back half of 2027 due to VAC committee timelines.
• International (OUS): Revenue grew 9.7% YoY; Direct markets grew 16% YoY (6th consecutive quarter of double-digit growth); Distributor markets grew 10% YoY after pulling forward orders in Q1; 60% of OUS revenue from distributors (vs. 50% guidance) impacting mix; Middle East market impacted by conflict but overall regions stable.

Market and Competitive Outlook:

• Category Growth: U.S. breast augmentation procedures grew 11% (2024–2025); market expansion driven by innovation (Preserve, Motiva) rather than pure share capture.
• Consumer Demand: Rising trend for smaller, natural-looking results ("ballerina/yoga breast" trend); consumer awareness increasing (Forbes, Allure features); 98% of surgeons report patients asking for Preserve by name.
• Market Share: Motiva estimated at 30% share of U.S. augmentation market as of September 2026; 85% Q2-to-Q3 reorder rate indicates high adoption stickiness.
• Competitive Strategy: Leveraging minimally invasive products as entry points; expanding portfolio breadth to increase surgeon options and patient accessibility.

Macro / Industry Outlook:

• Supply Chain: Strategic agreement with supplier NuCil secured to scale production; pricing structured around volume commitments with inflationary adjustments generally aligned to market trends; no major cost impact anticipated.
• Geopolitical: Middle East market performance impacted by ongoing conflict; general stability observed in other global regions.
• Seasonality: Q3 historically soft; Q4 showing strong start; distributor order timing noted as variable with tendency for pull-throughs.
• Regulatory: FDA approval anticipated for reconstruction indication (end of 2026/Q1 2027); evaluating regulatory pathways for ergonomics in Mia and Gem products in major markets.

Strategic Initiatives:

• Capacity & Supply: Strengthened silicone supply via NuCil agreement to support sustained growth and volume commitments.
• Commercial Expansion: Sales force increased to 55 reps (up from prior levels); adding leadership roles specifically for hospital network requirements; targeting increased utilization in U.S. accounts.
• Product Portfolio Expansion: Commercializing 105 cc Motiva sizes in U.S. by year-end; global size expansions for MIA and Preserve to accommodate broader patient demographics.
• Reconstruction Market Entry: Building hospital relationships with Motiva Flora Tissue Expander in 350+ facilities; preparing for VAC (Vendor Advisory Committee) processes (typically 3–6 months per facility) post-reconstruction implant approval.
• Operational Efficiency: Continued focus on operating leverage; Q3 achieved first positive free cash flow ($5.1M); scaling commercial model with improved gross margins.

Risks and Headwinds to Outlook:

• Seasonality: Q3 typically softest quarter; sequential revenue declines in minimally invasive attributed to European summer seasonality.
• Channel Mix: Higher mix of OUS distributor sales (lower margin % than direct) partially offset gross margin improvements; full-year guidance reflects this mix reality.
• Regulatory Timing: FDA approval dates for reconstruction cannot be predicted with certainty; VAC committee timelines at individual hospitals may vary (3–6 months).
• Geopolitical: Ongoing conflict in Middle East impacts regional order volume and performance.
• Utilization Rates: Adoption pace among existing surgeons depends on learning curves, scheduling patterns, and product familiarity.
• Market Variability: Distributor order timing remains variable; "pull-forward" effects possible in specific quarters.

Management Tone on the Future:

• Confidence: "Encouraged by the opportunities ahead"; "highly scalable financial model"; "meaningful opportunities" for 2027.
• Trend: Shift from "land and expand" account acquisition to "increasing utilization" and "margin expansion."
• Milestones: First positive free cash flow achieved in Q3 2026; viewed as a major inflection point validating the business model.
• Strategic Focus: Emphasis on innovation expanding the total market size rather than just capturing share; belief that 25% growth in 2027 is achievable without reconstruction fully ramping until late 2027.

Miscellaneous:

• Financial Structure: Refinance debt facility includes payment-in-kind interest provision providing >$5M quarterly interest savings initially.
• Product Specifics: Motiva Flora Tissue Expander now in 350+ facilities (up 14% in Q3).
• Investor Relations: Q3 2026 was the first quarter of positive free cash flow in company history; Q4 2026 starts strong, enabling guidance raise.